MX2020006436A - Compuestos inhibidores del blanco mecanistico de rapamicina (mtor). - Google Patents
Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).Info
- Publication number
- MX2020006436A MX2020006436A MX2020006436A MX2020006436A MX2020006436A MX 2020006436 A MX2020006436 A MX 2020006436A MX 2020006436 A MX2020006436 A MX 2020006436A MX 2020006436 A MX2020006436 A MX 2020006436A MX 2020006436 A MX2020006436 A MX 2020006436A
- Authority
- MX
- Mexico
- Prior art keywords
- mtor inhibitor
- inhibitor compounds
- compositions
- relates
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229940124302 mTOR inhibitor Drugs 0.000 title abstract 4
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
Abstract
La invención se relaciona con nuevos compuestos inhibidores de mTOR. Se caracteriza porque los compuestos inhibidores de mTOR son de la fórmula general (I). También se relaciona con composiciones que los comprenden, sus métodos de preparación y sus usos en composiciones como medicamento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1771402A FR3075795A1 (fr) | 2017-12-21 | 2017-12-21 | Nouveaux composes inhibiteurs de mtor |
PCT/EP2018/086074 WO2019122065A1 (fr) | 2017-12-21 | 2018-12-20 | Composes inhibiteurs de mtor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006436A true MX2020006436A (es) | 2020-09-17 |
Family
ID=62017455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006436A MX2020006436A (es) | 2017-12-21 | 2018-12-20 | Compuestos inhibidores del blanco mecanistico de rapamicina (mtor). |
Country Status (16)
Country | Link |
---|---|
US (1) | US11518767B2 (es) |
EP (1) | EP3727390B1 (es) |
JP (1) | JP2021506917A (es) |
KR (1) | KR20200103032A (es) |
CN (1) | CN111918654A (es) |
AU (1) | AU2018392761B2 (es) |
BR (1) | BR112020012201A2 (es) |
CA (1) | CA3086243A1 (es) |
CL (1) | CL2020001686A1 (es) |
FR (1) | FR3075795A1 (es) |
IL (1) | IL275531B2 (es) |
MX (1) | MX2020006436A (es) |
RU (1) | RU2020123899A (es) |
SA (1) | SA520412289B1 (es) |
SG (1) | SG11202005868XA (es) |
WO (1) | WO2019122065A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110407703A (zh) * | 2019-08-02 | 2019-11-05 | 深圳振强生物技术有限公司 | 吲哚布芬杂质的制备方法 |
WO2023285926A1 (en) | 2021-07-12 | 2023-01-19 | Galderma Holding SA | Synthesis of chiral substituted pyrazolopyrimidine compounds |
WO2023031738A1 (en) | 2021-08-31 | 2023-03-09 | Galderma Holding SA | Novel mtor inhibitor compounds |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0414533A (pt) | 2003-09-18 | 2006-11-07 | Conforma Therapeutics Corp | composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90 |
JP5335432B2 (ja) * | 2005-11-17 | 2013-11-06 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | 縮合2環系mTOR阻害剤 |
JP2011503103A (ja) | 2007-11-07 | 2011-01-27 | フォールドアールエックス ファーマシューティカルズ インコーポレーティッド | タンパク質輸送の調節方法 |
EA018144B1 (ru) | 2008-03-19 | 2013-05-30 | Оси Фармасьютикалз, Инк. | СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR |
TWI592411B (zh) | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | 激酶抑制劑之組合及其用途 |
US20140357651A1 (en) * | 2011-05-04 | 2014-12-04 | Yi Liu | Combination pharmaceutical compositions and uses thereof |
CA2835197A1 (en) * | 2011-05-06 | 2012-11-15 | Intellikine Llc | Treatment of polycystic disease |
EP2763985B1 (en) * | 2011-10-07 | 2016-06-22 | Cellzome Limited | {(4-(4-morpholino-dihydrothieno[3,4-d]pyrimidin-2-yl)aryl}urea or carbamate derivatives as mtor inhibitors |
US20130209543A1 (en) | 2011-11-23 | 2013-08-15 | Intellikine Llc | Enhanced treatment regimens using mtor inhibitors |
CA2833701A1 (en) * | 2013-11-19 | 2015-05-19 | Pharmascience Inc. | Protein kinase inhibitors |
US11643414B2 (en) * | 2016-04-29 | 2023-05-09 | Merck Patent Gmbh | Materials for organic electroluminescent devices |
FR3075794A1 (fr) | 2017-12-21 | 2019-06-28 | Galderma Research & Development | Nouveaux composes inhibiteurs de mtor |
-
2017
- 2017-12-21 FR FR1771402A patent/FR3075795A1/fr active Pending
-
2018
- 2018-12-20 JP JP2020534447A patent/JP2021506917A/ja not_active Ceased
- 2018-12-20 KR KR1020207020410A patent/KR20200103032A/ko not_active Application Discontinuation
- 2018-12-20 RU RU2020123899A patent/RU2020123899A/ru unknown
- 2018-12-20 EP EP18826025.1A patent/EP3727390B1/fr active Active
- 2018-12-20 AU AU2018392761A patent/AU2018392761B2/en active Active
- 2018-12-20 WO PCT/EP2018/086074 patent/WO2019122065A1/fr unknown
- 2018-12-20 CA CA3086243A patent/CA3086243A1/en active Pending
- 2018-12-20 IL IL275531A patent/IL275531B2/en unknown
- 2018-12-20 CN CN201880090046.3A patent/CN111918654A/zh active Pending
- 2018-12-20 SG SG11202005868XA patent/SG11202005868XA/en unknown
- 2018-12-20 BR BR112020012201-7A patent/BR112020012201A2/pt unknown
- 2018-12-20 MX MX2020006436A patent/MX2020006436A/es unknown
-
2020
- 2020-06-19 CL CL2020001686A patent/CL2020001686A1/es unknown
- 2020-06-19 US US16/907,122 patent/US11518767B2/en active Active
- 2020-06-21 SA SA520412289A patent/SA520412289B1/ar unknown
Also Published As
Publication number | Publication date |
---|---|
FR3075795A1 (fr) | 2019-06-28 |
SG11202005868XA (en) | 2020-07-29 |
CL2020001686A1 (es) | 2020-11-27 |
CA3086243A1 (en) | 2019-06-27 |
SA520412289B1 (ar) | 2022-07-28 |
EP3727390A1 (fr) | 2020-10-28 |
EP3727390B1 (fr) | 2023-03-22 |
CN111918654A (zh) | 2020-11-10 |
IL275531B2 (en) | 2023-09-01 |
JP2021506917A (ja) | 2021-02-22 |
RU2020123899A (ru) | 2022-01-21 |
IL275531A (en) | 2020-08-31 |
RU2020123899A3 (es) | 2022-02-17 |
BR112020012201A2 (pt) | 2020-11-24 |
AU2018392761A1 (en) | 2020-07-09 |
WO2019122065A1 (fr) | 2019-06-27 |
US20200317683A1 (en) | 2020-10-08 |
AU2018392761B2 (en) | 2023-09-14 |
US11518767B2 (en) | 2022-12-06 |
KR20200103032A (ko) | 2020-09-01 |
IL275531B1 (en) | 2023-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018010427A (es) | Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion. | |
TN2018000276A1 (en) | Inhibitors of receptor-interacting protein kinase 1. | |
MX2018002986A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos. | |
PH12018500408A1 (en) | Bicyclic compounds as atx inhibitors | |
NZ739676A (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
PH12016500467A1 (en) | Aminoheteroarlyl benzamides as kinase inhibitors | |
GEP20186887B (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
MX2020006434A (es) | Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor). | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
PH12017502051A1 (en) | TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | |
PH12018500409A1 (en) | New bicyclic compounds as dual atx/ca inhibitors | |
MX2016002794A (es) | Compuestos antiproliferativos. | |
MX2016016143A (es) | Compuestos de [1,2,4]triazol sustituido. | |
PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
GEP201706725B (en) | Compounds and compositions as inhibitors of mek | |
MX2022010755A (es) | Inhibidores de quinasa y usos de los mismos. | |
GEP201606598B (en) | Heteroaromatic compounds as dopamine d1 ligands | |
UA117032C2 (uk) | Селективний інгібітор фосфатидилінозитол-3-кінази-гамма | |
PH12017500737B1 (en) | Kcnq2-5 channel activator | |
PH12016500347A1 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
MX2015016332A (es) | Inhibidores de alk biciclicos fusionados. | |
MX2020006436A (es) | Compuestos inhibidores del blanco mecanistico de rapamicina (mtor). | |
MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
MX2017008076A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß. |